Article PDF first page preview

First page of The Utility of Copeptin Measurement in Hospitalized Pediatric Patients with SIADH

Introduction: Hyponatremia is common in hospitalized pediatric patients and in many cases the diagnosis of the Syndrome of Inappropriate Antidiuretic Secretion (SIADH) remains challenging, with no gold standard for diagnosis. We assessed factors associated with hyponatremia in pediatric patients clinically diagnosed with SIADH, and examined the validity of copeptin level as a useful tool to distinguish SIADH from non-SIADH causes of hyponatremia. Methods: This observational study retrospectively analyzed 19 patients admitted to Children’s Hospital of Orange County in 2021-2024 for hyponatremia. ROC analyses assessed the ability of copeptin level to distinguish diagnostic groups, determining the optimal threshold for classification. Results: Pediatric patients with a diagnosis of SIADH had a significantly higher average urine sodium level (135.4 vs. 68.3 p=.036), and higher average copeptin level (median=14.3 vs. 5.7, p=.036). ROC analyses determined copeptin had good ability to differentiate a clinical diagnosis of SIADH from non-SIADH causes of hyponatremia with Sensitivity 83%, Specificity 71%, PVP 83%, NPV 71%). A significantly higher percentage of patients with copeptin level greater than 8.0 pmol/L were diagnosed with SIADH (83.3% vs. 28.6%), p=.017). Conclusion: Copeptin levels correlated with a clinical diagnosis of SIADH in hospitalized pediatric patients, particularly if elevated above 8.0 pmol/L at the time of hyponatremia, and the patient met the Schwartz and Bartter clinical criteria for SIADH. In some cases of SIADH, copeptin levels may be in normal range, however, could be considered inappropriately high for the degree of hyponatremia.

Journal Section:
Research Article
This content is only available via PDF.
The Author(s). Published by S. Karger AG, Basel
Open Access License / Drug Dosage / Disclaimer
This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License .
Attribution-NonCommercial